Levin Group announced that it has been engaged by Novalar Pharmaceuticals to develop a program to demonstrate to dental professionals the value of OraVerse as an effective routine treatment in cases where anesthesia reversal is appropriate.

OraVerse is the first and only anesthesia reversal agent that restores normal sensation twice as fast and accelerates return to normal function so patients can speak, smile, and drink normally, the companies said in a press release.

An international dental practice management consulting firm, Levin Group works with numerous dental corporations to help them market their products and technologies and integrate them into dental practices.

Local anesthetic-reversal drug approved

Novalar launches first anesthesia reversal agent

Levin Group, ABEL Dental form alliance

Biolase, Levin Group partner to promote dental lasers

Procter & Gamble, Levin Group offer 'Dream Office Sweepstakes'